Warfarin therapy
231 results
1 - 100Warfarin therapy
- Essentials
- Indications for warfarin therapy
- Complications
- References
- Contraindications to warfarin therapy
- Initiation and intensity of warfarin therapy
- INR determinations
- Interactions
- Duration of the treatment
- Pregnancy and breastfeeding
- Temporary reduction of warfarin dose; bridging therapy
- Thrombosis despite warfarin therapy
Don't add aspirin to warfarin therapy except with mechanical heart valve
Discontinuing warfarin therapy indefinitely after GI bleeding assoc with worse outcomes
Warfarin or antiplatelet therapy for stroke prevention in patients with non-valvular atrial fibrillation
Continued warfarin better than bridging therapy for pacemaker or defibrillator surgery (BRUISE CONTROL)
Antithrombotic agents in primary health care
NOAC versus warfarin post‐PCI in atrial fibrillation
Indications for and implementation of anticoagulant therapy in atrial fibrillation
Benefits to resuming warfarin in patients with atrial fibrillation after intracranial bleeds
Warfarin superior to antiplatelet treatment for A Fib
Tinzaparin no better than warfarin in preventing recurrent VTE in adults with cancer
Warfarin can safely be held for the short term
6 months of warfarin after aortic valve replacement reduces risk of CV death
Continuing warfarin for 18 months after unprovoked PE reduces risk of recurrent VTE
Warfarin: damned if you do, damned if you don't
Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter: Cochrane systematic review
Vitamins
Bleeding risk with warfarin high among elderly, especially older than 80
Clinically significant bleeding occurs in 3.8% per year of pts aged 65+ years using warfarin
Many patients using warfarin also take aspirin
Warfarin initiation nomograms for venous thromboembolism: Cochrane systematic review
Dual therapy with dabigatran and clopidogrel preferred after PCI for patients with AF (RE-DUAL PCI)
Heart valve operation: patient follow-up and complications
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks: Cochrane systematic review
NOACs preferred over warfarin for nonvalvular atrial fibrillation in patients also taking low-dose aspirin
Antiplatelet versus anticoagulation treatment for people with heart failure in sinus rhythm
More harm than good with bridge therapy in low-risk VTE patients
Genetic information does not add benefit to a clinical algorithm for warfarin management
Dabigatran reduces risk of stroke and embolism in patients with AF
Closure of PFO similar to medical therapy for cryptogenic stroke or TIA
Extended anticoagulation may be helpul for patients with unprovoked VTE or PE
Optimal loading dose of warfarin for the initiation of oral anticoagulation
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease
Genotype-guided perioperative warfarin dosing may not be superior to algorithm-guided dosing
Mitral regurgitation
Non‐vitamin K antagonist oral anticoagulants (NOACs) after transcatheter aortic valve replacement (TAVR): a network meta‐analysis
Anticoagulation for heart failure in sinus rhythm
Vitamin K for improved anticoagulation control in patients receiving warfarin
Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks: Cochrane systematic review
Percutaneous left atrial appendage closure reduces AF stroke risk
Rivaroxaban + clopidogrel causes somewhat less bleeding than triple therapy in patients with AF undergoing PCI